Comparison of Amiodarone and Propafenone in Blanking Period after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation: A Propensity Score-Matched Study

Background. Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF). However, it is not known which one is better in reducing early recurrence (ER) during the blanking period (the first three months after catheter ablation). Objective. To compa...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2020, Vol.2020 (2020), p.1-8
Main Authors: Xu, Zhe, Chen, XueHai, Zhang, FeiLong, Fan, Lin, Chen, LiangLong, Gong, KeZeng, Lin, JingJing, Huang, RongDa, Zhang, Yan
Format: Article
Language:English
Subjects:
Ablation
Aged
Amiodarone
Amiodarone - administration & dosage
Amiodarone - adverse effects
Arrhythmia
Atrial fibrillation
Atrial Fibrillation - physiopathology
Atrial Fibrillation - therapy
Blanking
Cardiac arrhythmia
Cardiovascular disease
Cardiovascular system
Care and treatment
Catheter Ablation
Catheters
Digestive system
Dosage and administration
Drug dosages
Electrocardiography
Female
Fibrillation
Humans
Hyperthyroidism
Hypothyroidism
Laboratories
Male
Medical instruments
Middle Aged
Patient outcomes
Propafenone
Propafenone - administration & dosage
Propafenone - adverse effects
Radio frequency
Radiofrequency ablation
Recurrence
Side effects
Sinuses
Thyroid gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Amiodarone and propafenone are commonly used to maintain sinus rhythm in patients with atrial fibrillation (AF). However, it is not known which one is better in reducing early recurrence (ER) during the blanking period (the first three months after catheter ablation). Objective. To compare the efficacy and safety of amiodarone and propafenone in reducing ER during the blanking period after radiofrequency catheter ablation (RFCA) in AF patients. Materials and Methods. A total of 694 patients who underwent their first RFCA between May 2014 and May 2018 were enrolled in this retrospective study. Subsequently, 202 patients were excluded according to the exclusion criteria. The remaining 492 patients were divided into two groups based on the choice of antiarrhythmic drugs (AADs) (amiodarone or propafenone) in the blanking period. The primary outcomes were incidence of ER and AAD-associated adverse effects during the blanking period after RFCA. Propensity score matching (PSM) analyses were used to compare the outcomes of the two groups while controlling for confounders. Results. Among the 492 patients who took AADs in the blanking period (187 amiodarone and 305 propafenone), PSM selected 135 unique pairs of patients with similar characteristics. Amiodarone was associated with a lower ER incidence rate (23.7% versus 48.9%, p
ISSN:2314-6133
2314-6141
DOI:10.1155/2020/1835181